<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2022-08-28T01:21:49.033Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men]]></title>
        <id>pubmed:36018819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36018819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Little is known regarding the potential relationship between clonal hematopoiesis (CH) of indeterminate potential (CHIP), which is the expansion of hematopoietic stem cells with somatic mutations, and risk of prostate cancer, the fifth leading cause of cancer death of men worldwide. We evaluated the association of age-related CHIP with overall and aggressive prostate cancer risk in two large whole-exome sequencing studies of 75 047 European ancestry men, including 7663 prostate cancer cases,...]]></summary>
        <author>
            <name>Anqi Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysmegakaryopoiesis and Transient Mild Increase in Bone Marrow Blasts in Patients With Aplastic Anemia Treated With Eltrombopag May Be Signs of Hematologic Improvement and Not Portend Clonal Evolution]]></title>
        <id>pubmed:36018052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36018052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Dysmegakaryopoiesis without micromegakaryocytes and a transient increase of less than 5% in bone marrow blast count may be signs of hematologic improvement with eltrombopag for patients with AA.]]></summary>
        <author>
            <name>Akira Matsuda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm]]></title>
        <id>pubmed:36013314</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36013314/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell aging, through the acquisition of somatic mutations, gives rise to clonal hematopoiesis (CH). While a high prevalence of CH has been described in otherwise healthy older adults, CH confers an increased risk of both hematologic and non-hematologic diseases. Classification of CH into clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) further describes this neoplastic myeloid precursor state and stratifies...]]></summary>
        <author>
            <name>Charles Gaulin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Azanucleosides Affect Myeloid Cell Fate]]></title>
        <id>pubmed:36010665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36010665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The azanucleosides decitabine and azacytidine are used widely in the treatment of myeloid neoplasia and increasingly in the context of combination therapies. Although they were long regarded as being largely interchangeable in their function as hypomethylating agents, the azanucleosides actually have different mechanisms of action; decitabine interferes primarily with the methylation of DNA and azacytidine with that of RNA. Here, we examine the role of DNA methylation in the lineage commitment...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics]]></title>
        <id>pubmed:36010306</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36010306/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Targeted sequencing of circulating cell-free DNA (cfDNA) is used in routine clinical diagnostics for the identification of predictive biomarkers in cancer patients in an advanced stage. The presence of KRAS mutations associated with clonal hematopoiesis of indeterminate potential (CHIP) might represent a confounding factor. We used an amplicon-based targeted sequencing panel, covering selected regions of 52 genes, for circulating cell-free total nucleic acid (cfTNA) analysis of 495 plasma...]]></summary>
        <author>
            <name>Cristin Roma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TERT and TET2 Genetic Variants Affect Leukocyte Telomere Length and Clinical Outcome in Coronary Artery Disease Patients-A Possible Link to Clonal Hematopoiesis]]></title>
        <id>pubmed:36009574</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36009574/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited and acquired mutations in hematopoietic stem cells can cause clonal expansion with increased risk of cardiovascular disease (CVD), a condition known for the clonal hematopoiesis of indeterminate potential (CHIP). Inherited genetic variants in two CHIP-associated genome loci, the telomerase gene telomerase enzyme reverse transcriptase (TERT) (rs7705526) and the epigenetic regulator ten-eleven translocation 2 (TET2) (rs2454206), were investigated in 1001 patients with stable coronary...]]></summary>
        <author>
            <name>Trine B Opstad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men]]></title>
        <id>pubmed:36018819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36018819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Little is known regarding the potential relationship between clonal hematopoiesis (CH) of indeterminate potential (CHIP), which is the expansion of hematopoietic stem cells with somatic mutations, and risk of prostate cancer, the fifth leading cause of cancer death of men worldwide. We evaluated the association of age-related CHIP with overall and aggressive prostate cancer risk in two large whole-exome sequencing studies of 75 047 European ancestry men, including 7663 prostate cancer cases,...]]></summary>
        <author>
            <name>Anqi Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysmegakaryopoiesis and Transient Mild Increase in Bone Marrow Blasts in Patients With Aplastic Anemia Treated With Eltrombopag May Be Signs of Hematologic Improvement and Not Portend Clonal Evolution]]></title>
        <id>pubmed:36018052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36018052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Dysmegakaryopoiesis without micromegakaryocytes and a transient increase of less than 5% in bone marrow blast count may be signs of hematologic improvement with eltrombopag for patients with AA.]]></summary>
        <author>
            <name>Akira Matsuda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm]]></title>
        <id>pubmed:36013314</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36013314/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell aging, through the acquisition of somatic mutations, gives rise to clonal hematopoiesis (CH). While a high prevalence of CH has been described in otherwise healthy older adults, CH confers an increased risk of both hematologic and non-hematologic diseases. Classification of CH into clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) further describes this neoplastic myeloid precursor state and stratifies...]]></summary>
        <author>
            <name>Charles Gaulin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Azanucleosides Affect Myeloid Cell Fate]]></title>
        <id>pubmed:36010665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36010665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The azanucleosides decitabine and azacytidine are used widely in the treatment of myeloid neoplasia and increasingly in the context of combination therapies. Although they were long regarded as being largely interchangeable in their function as hypomethylating agents, the azanucleosides actually have different mechanisms of action; decitabine interferes primarily with the methylation of DNA and azacytidine with that of RNA. Here, we examine the role of DNA methylation in the lineage commitment...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics]]></title>
        <id>pubmed:36010306</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36010306/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Targeted sequencing of circulating cell-free DNA (cfDNA) is used in routine clinical diagnostics for the identification of predictive biomarkers in cancer patients in an advanced stage. The presence of KRAS mutations associated with clonal hematopoiesis of indeterminate potential (CHIP) might represent a confounding factor. We used an amplicon-based targeted sequencing panel, covering selected regions of 52 genes, for circulating cell-free total nucleic acid (cfTNA) analysis of 495 plasma...]]></summary>
        <author>
            <name>Cristin Roma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TERT and TET2 Genetic Variants Affect Leukocyte Telomere Length and Clinical Outcome in Coronary Artery Disease Patients-A Possible Link to Clonal Hematopoiesis]]></title>
        <id>pubmed:36009574</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36009574/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited and acquired mutations in hematopoietic stem cells can cause clonal expansion with increased risk of cardiovascular disease (CVD), a condition known for the clonal hematopoiesis of indeterminate potential (CHIP). Inherited genetic variants in two CHIP-associated genome loci, the telomerase gene telomerase enzyme reverse transcriptase (TERT) (rs7705526) and the epigenetic regulator ten-eleven translocation 2 (TET2) (rs2454206), were investigated in 1001 patients with stable coronary...]]></summary>
        <author>
            <name>Trine B Opstad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia]]></title>
        <id>pubmed:36028583</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36028583/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Eltrombopag (EPAG), a thrombopoietin receptor agonist, was approved for the treatment of severe aplastic anemia (SAA) combined with immunosuppressive therapy (IST). However, the effects of real-life use of low doses of EPAG combined with rabbit antithymocyte globulin (ATG)-based IST in Asian patients with SAA are yet unknown. A total of 121 previously untreated Chinese patients with SAA were enrolled in a multicenter registry of the Chinese Eastern Collaboration Group of Anemia (2014-2020): 67...]]></summary>
        <author>
            <name>Yuanyuan Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm]]></title>
        <id>pubmed:36013314</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36013314/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell aging, through the acquisition of somatic mutations, gives rise to clonal hematopoiesis (CH). While a high prevalence of CH has been described in otherwise healthy older adults, CH confers an increased risk of both hematologic and non-hematologic diseases. Classification of CH into clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) further describes this neoplastic myeloid precursor state and stratifies...]]></summary>
        <author>
            <name>Charles Gaulin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm]]></title>
        <id>pubmed:36013314</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36013314/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell aging, through the acquisition of somatic mutations, gives rise to clonal hematopoiesis (CH). While a high prevalence of CH has been described in otherwise healthy older adults, CH confers an increased risk of both hematologic and non-hematologic diseases. Classification of CH into clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) further describes this neoplastic myeloid precursor state and stratifies...]]></summary>
        <author>
            <name>Charles Gaulin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current status and future perspectives in targeted therapy of NPM1-mutated AML]]></title>
        <id>pubmed:36008542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36008542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is predominantly located in the nucleolus and exerts multiple functions, including regulation of centrosome duplication, ribosome biogenesis and export, histone assembly, maintenance of genomic stability and response to nucleolar stress. NPM1 mutations are the most common genetic alteration in acute myeloid leukemia (AML), detected in about 30-35% of adult AML and more than 50% of AML with normal karyotype. Because of its...]]></summary>
        <author>
            <name>Roberta Ranieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current status and future perspectives in targeted therapy of NPM1-mutated AML]]></title>
        <id>pubmed:36008542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36008542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is predominantly located in the nucleolus and exerts multiple functions, including regulation of centrosome duplication, ribosome biogenesis and export, histone assembly, maintenance of genomic stability and response to nucleolar stress. NPM1 mutations are the most common genetic alteration in acute myeloid leukemia (AML), detected in about 30-35% of adult AML and more than 50% of AML with normal karyotype. Because of its...]]></summary>
        <author>
            <name>Roberta Ranieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision diagnostics in cancer: Predict, prevent, and personalize]]></title>
        <id>pubmed:36008001</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36008001/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past two decades since the first sequencing of the human genome, clinical genomics has undergone a renaissance with the advent of next generation sequencing (NGS) technologies. Whole genome sequencing is now increasingly available in the clinical setting at a fraction of the cost of the human genome reference sequence, and with turnaround times as short as 7-10days. Clinical genetics-based management has become more tractable with improved payer reimbursement and increased availability of...]]></summary>
        <author>
            <name>Judy S Crabtree</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision diagnostics in cancer: Predict, prevent, and personalize]]></title>
        <id>pubmed:36008001</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36008001/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past two decades since the first sequencing of the human genome, clinical genomics has undergone a renaissance with the advent of next generation sequencing (NGS) technologies. Whole genome sequencing is now increasingly available in the clinical setting at a fraction of the cost of the human genome reference sequence, and with turnaround times as short as 7-10days. Clinical genetics-based management has become more tractable with improved payer reimbursement and increased availability of...]]></summary>
        <author>
            <name>Judy S Crabtree</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lipids and the cancer stemness regulatory system in acute myeloid leukemia]]></title>
        <id>pubmed:35996953</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996953/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a heterogeneous disease of impaired myeloid differentiation and a caricature of normal hematopoiesis. Leukemic stem cells (LSCs) are responsible for long-term clonal propagation in AML just as hematopoietic stem cells (HSCs) sustain lifelong hematopoiesis. LSCs are often resistant to standard chemotherapy and are responsible for clinical relapse. Although AML is highly heterogeneous, determinants of stemness are prognostic for AML patient survival and can predict...]]></summary>
        <author>
            <name>Isabel N X Lim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lipids and the cancer stemness regulatory system in acute myeloid leukemia]]></title>
        <id>pubmed:35996953</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996953/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a heterogeneous disease of impaired myeloid differentiation and a caricature of normal hematopoiesis. Leukemic stem cells (LSCs) are responsible for long-term clonal propagation in AML just as hematopoietic stem cells (HSCs) sustain lifelong hematopoiesis. LSCs are often resistant to standard chemotherapy and are responsible for clinical relapse. Although AML is highly heterogeneous, determinants of stemness are prognostic for AML patient survival and can predict...]]></summary>
        <author>
            <name>Isabel N X Lim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lipids and the cancer stemness regulatory system in acute myeloid leukemia]]></title>
        <id>pubmed:35996953</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996953/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a heterogeneous disease of impaired myeloid differentiation and a caricature of normal hematopoiesis. Leukemic stem cells (LSCs) are responsible for long-term clonal propagation in AML just as hematopoietic stem cells (HSCs) sustain lifelong hematopoiesis. LSCs are often resistant to standard chemotherapy and are responsible for clinical relapse. Although AML is highly heterogeneous, determinants of stemness are prognostic for AML patient survival and can predict...]]></summary>
        <author>
            <name>Isabel N X Lim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lipids and the cancer stemness regulatory system in acute myeloid leukemia]]></title>
        <id>pubmed:35996953</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996953/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a heterogeneous disease of impaired myeloid differentiation and a caricature of normal hematopoiesis. Leukemic stem cells (LSCs) are responsible for long-term clonal propagation in AML just as hematopoietic stem cells (HSCs) sustain lifelong hematopoiesis. LSCs are often resistant to standard chemotherapy and are responsible for clinical relapse. Although AML is highly heterogeneous, determinants of stemness are prognostic for AML patient survival and can predict...]]></summary>
        <author>
            <name>Isabel N X Lim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lipids and the cancer stemness regulatory system in acute myeloid leukemia]]></title>
        <id>pubmed:35996953</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996953/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a heterogeneous disease of impaired myeloid differentiation and a caricature of normal hematopoiesis. Leukemic stem cells (LSCs) are responsible for long-term clonal propagation in AML just as hematopoietic stem cells (HSCs) sustain lifelong hematopoiesis. LSCs are often resistant to standard chemotherapy and are responsible for clinical relapse. Although AML is highly heterogeneous, determinants of stemness are prognostic for AML patient survival and can predict...]]></summary>
        <author>
            <name>Isabel N X Lim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Homeostasis limits keratinocyte evolution]]></title>
        <id>pubmed:35998218</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35998218/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent studies have revealed that normal human tissues accumulate many somatic mutations. In particular, human skin is riddled with mutations, with multiple subclones of variable sizes. Driver mutations are frequent and tend to have larger subclone sizes, suggesting selection. To begin to understand the histories encoded by these complex somatic mutations, we incorporated genomes into a simple agent-based skin-cell model whose prime directive is homeostasis. In this model, stem-cell survival is...]]></summary>
        <author>
            <name>Ryan O Schenck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Homeostasis limits keratinocyte evolution]]></title>
        <id>pubmed:35998218</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35998218/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent studies have revealed that normal human tissues accumulate many somatic mutations. In particular, human skin is riddled with mutations, with multiple subclones of variable sizes. Driver mutations are frequent and tend to have larger subclone sizes, suggesting selection. To begin to understand the histories encoded by these complex somatic mutations, we incorporated genomes into a simple agent-based skin-cell model whose prime directive is homeostasis. In this model, stem-cell survival is...]]></summary>
        <author>
            <name>Ryan O Schenck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Homeostasis limits keratinocyte evolution]]></title>
        <id>pubmed:35998218</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35998218/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent studies have revealed that normal human tissues accumulate many somatic mutations. In particular, human skin is riddled with mutations, with multiple subclones of variable sizes. Driver mutations are frequent and tend to have larger subclone sizes, suggesting selection. To begin to understand the histories encoded by these complex somatic mutations, we incorporated genomes into a simple agent-based skin-cell model whose prime directive is homeostasis. In this model, stem-cell survival is...]]></summary>
        <author>
            <name>Ryan O Schenck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside]]></title>
        <id>pubmed:35990601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35990601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While the underlying genetic alterations and biology of acute myeloid leukemia (AML), an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid cells, have been gradually unraveled in the last decades, translation into clinical treatment approaches has only just begun. High relapse rates remain a major challenge in AML therapy and are to a large extent attributed to the persistence of treatment-resistant leukemic stem cells (LSCs). The Hedgehog (HH)...]]></summary>
        <author>
            <name>Suzana Tesanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside]]></title>
        <id>pubmed:35990601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35990601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While the underlying genetic alterations and biology of acute myeloid leukemia (AML), an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid cells, have been gradually unraveled in the last decades, translation into clinical treatment approaches has only just begun. High relapse rates remain a major challenge in AML therapy and are to a large extent attributed to the persistence of treatment-resistant leukemic stem cells (LSCs). The Hedgehog (HH)...]]></summary>
        <author>
            <name>Suzana Tesanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside]]></title>
        <id>pubmed:35990601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35990601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While the underlying genetic alterations and biology of acute myeloid leukemia (AML), an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid cells, have been gradually unraveled in the last decades, translation into clinical treatment approaches has only just begun. High relapse rates remain a major challenge in AML therapy and are to a large extent attributed to the persistence of treatment-resistant leukemic stem cells (LSCs). The Hedgehog (HH)...]]></summary>
        <author>
            <name>Suzana Tesanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside]]></title>
        <id>pubmed:35990601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35990601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While the underlying genetic alterations and biology of acute myeloid leukemia (AML), an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid cells, have been gradually unraveled in the last decades, translation into clinical treatment approaches has only just begun. High relapse rates remain a major challenge in AML therapy and are to a large extent attributed to the persistence of treatment-resistant leukemic stem cells (LSCs). The Hedgehog (HH)...]]></summary>
        <author>
            <name>Suzana Tesanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside]]></title>
        <id>pubmed:35990601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35990601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While the underlying genetic alterations and biology of acute myeloid leukemia (AML), an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid cells, have been gradually unraveled in the last decades, translation into clinical treatment approaches has only just begun. High relapse rates remain a major challenge in AML therapy and are to a large extent attributed to the persistence of treatment-resistant leukemic stem cells (LSCs). The Hedgehog (HH)...]]></summary>
        <author>
            <name>Suzana Tesanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside]]></title>
        <id>pubmed:35990601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35990601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While the underlying genetic alterations and biology of acute myeloid leukemia (AML), an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid cells, have been gradually unraveled in the last decades, translation into clinical treatment approaches has only just begun. High relapse rates remain a major challenge in AML therapy and are to a large extent attributed to the persistence of treatment-resistant leukemic stem cells (LSCs). The Hedgehog (HH)...]]></summary>
        <author>
            <name>Suzana Tesanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma]]></title>
        <id>pubmed:35996174</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996174/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings suggest ITH as a potential unfavorable prognostic factor in PTC and highlight the dynamic changes in different clinical stages of PTC, providing some clues for the precision medicine and suggesting different diagnostic decisions depending on the clinical stages of patients. Finally, complete clear guidelines to define risk stratification of PTC patients are lacking; thus, this work could contribute to defining patients who need more aggressive treatments and, in turn,...]]></summary>
        <author>
            <name>Ornella Affinito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma]]></title>
        <id>pubmed:35996174</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996174/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings suggest ITH as a potential unfavorable prognostic factor in PTC and highlight the dynamic changes in different clinical stages of PTC, providing some clues for the precision medicine and suggesting different diagnostic decisions depending on the clinical stages of patients. Finally, complete clear guidelines to define risk stratification of PTC patients are lacking; thus, this work could contribute to defining patients who need more aggressive treatments and, in turn,...]]></summary>
        <author>
            <name>Ornella Affinito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma]]></title>
        <id>pubmed:35996174</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996174/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings suggest ITH as a potential unfavorable prognostic factor in PTC and highlight the dynamic changes in different clinical stages of PTC, providing some clues for the precision medicine and suggesting different diagnostic decisions depending on the clinical stages of patients. Finally, complete clear guidelines to define risk stratification of PTC patients are lacking; thus, this work could contribute to defining patients who need more aggressive treatments and, in turn,...]]></summary>
        <author>
            <name>Ornella Affinito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma]]></title>
        <id>pubmed:35996174</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996174/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings suggest ITH as a potential unfavorable prognostic factor in PTC and highlight the dynamic changes in different clinical stages of PTC, providing some clues for the precision medicine and suggesting different diagnostic decisions depending on the clinical stages of patients. Finally, complete clear guidelines to define risk stratification of PTC patients are lacking; thus, this work could contribute to defining patients who need more aggressive treatments and, in turn,...]]></summary>
        <author>
            <name>Ornella Affinito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma]]></title>
        <id>pubmed:35996174</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35996174/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings suggest ITH as a potential unfavorable prognostic factor in PTC and highlight the dynamic changes in different clinical stages of PTC, providing some clues for the precision medicine and suggesting different diagnostic decisions depending on the clinical stages of patients. Finally, complete clear guidelines to define risk stratification of PTC patients are lacking; thus, this work could contribute to defining patients who need more aggressive treatments and, in turn,...]]></summary>
        <author>
            <name>Ornella Affinito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIPing away the progression potential of CHIP: A new reality in the making]]></title>
        <id>pubmed:35989137</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35989137/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Over the past few years, we have gained a deeper understanding of clonal hematopoiesis of indeterminate potential (CHIP), especially with regard to the epidemiology, clinical sequelae, and mechanical aspects. However, interventional strategies to prevent or delay the potential negative consequences of CHIP remain underdeveloped. In this review, we highlight the latest updates on clonal hematopoiesis research, including molecular mechanisms and clinical implications, with a particular focus on...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIPing away the progression potential of CHIP: A new reality in the making]]></title>
        <id>pubmed:35989137</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35989137/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Over the past few years, we have gained a deeper understanding of clonal hematopoiesis of indeterminate potential (CHIP), especially with regard to the epidemiology, clinical sequelae, and mechanical aspects. However, interventional strategies to prevent or delay the potential negative consequences of CHIP remain underdeveloped. In this review, we highlight the latest updates on clonal hematopoiesis research, including molecular mechanisms and clinical implications, with a particular focus on...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIPing away the progression potential of CHIP: A new reality in the making]]></title>
        <id>pubmed:35989137</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35989137/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Over the past few years, we have gained a deeper understanding of clonal hematopoiesis of indeterminate potential (CHIP), especially with regard to the epidemiology, clinical sequelae, and mechanical aspects. However, interventional strategies to prevent or delay the potential negative consequences of CHIP remain underdeveloped. In this review, we highlight the latest updates on clonal hematopoiesis research, including molecular mechanisms and clinical implications, with a particular focus on...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIPing away the progression potential of CHIP: A new reality in the making]]></title>
        <id>pubmed:35989137</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35989137/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Over the past few years, we have gained a deeper understanding of clonal hematopoiesis of indeterminate potential (CHIP), especially with regard to the epidemiology, clinical sequelae, and mechanical aspects. However, interventional strategies to prevent or delay the potential negative consequences of CHIP remain underdeveloped. In this review, we highlight the latest updates on clonal hematopoiesis research, including molecular mechanisms and clinical implications, with a particular focus on...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIPing away the progression potential of CHIP: A new reality in the making]]></title>
        <id>pubmed:35989137</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35989137/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Over the past few years, we have gained a deeper understanding of clonal hematopoiesis of indeterminate potential (CHIP), especially with regard to the epidemiology, clinical sequelae, and mechanical aspects. However, interventional strategies to prevent or delay the potential negative consequences of CHIP remain underdeveloped. In this review, we highlight the latest updates on clonal hematopoiesis research, including molecular mechanisms and clinical implications, with a particular focus on...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIPing away the progression potential of CHIP: A new reality in the making]]></title>
        <id>pubmed:35989137</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35989137/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Over the past few years, we have gained a deeper understanding of clonal hematopoiesis of indeterminate potential (CHIP), especially with regard to the epidemiology, clinical sequelae, and mechanical aspects. However, interventional strategies to prevent or delay the potential negative consequences of CHIP remain underdeveloped. In this review, we highlight the latest updates on clonal hematopoiesis research, including molecular mechanisms and clinical implications, with a particular focus on...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms]]></title>
        <id>pubmed:35986863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition.]]></summary>
        <author>
            <name>Anmol Baranwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors]]></title>
        <id>pubmed:35984598</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35984598/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: To discuss the current treatment paradigm, review novel targets, and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in the management of myelofibrosis (MF).]]></summary>
        <author>
            <name>Julian A Waksal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia]]></title>
        <id>pubmed:35986270</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986270/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In summary, the single cell RNA data underpinned the tumor heterogeneity not only amongst patient blasts with similar initiating mutations but also between each Dx-Re pair. Our results suggest alternatively and currently unappreciated and unexplored mechanisms leading to therapeutic resistance and AML recurrence.]]></summary>
        <author>
            <name>Yanan Zhai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SCONCE2: jointly inferring single cell copy number profiles and tumor evolutionary distances]]></title>
        <id>pubmed:35986254</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35986254/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: SCONCE2 jointly estimates copy number profiles and a distance metric for inferring tumor phylogenies in single cell whole genome tumor sequencing across multiple cells, enabling deeper understandings of tumor evolution.]]></summary>
        <author>
            <name>Sandra Hui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes]]></title>
        <id>pubmed:35979721</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35979721/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a selective inhibitor of anti-apoptotic protein B-cell lymphoma-2 (BCL2), has yielded impressive responses in older patients with acute myeloid leukemia (AML) and high risk MDS. BCL2 family anti-apoptotic...]]></summary>
        <author>
            <name>Melissa A Fischer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts]]></title>
        <id>pubmed:35978153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35978153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver...]]></summary>
        <author>
            <name>Agnieszka Brojakowska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity]]></title>
        <id>pubmed:35977503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35977503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses...]]></summary>
        <author>
            <name>Natalia Miheecheva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients]]></title>
        <id>pubmed:35971851</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35971851/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing...]]></summary>
        <author>
            <name>Fernando L Scolari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis]]></title>
        <id>pubmed:35970010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35970010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Clonal hematopoiesis, a precursor to myelodysplastic syndromes (MDS), constitutes a novel cardiovascular disease (CVD) risk factor, causing growing interest in cardiovascular outcomes in MDS. Rurality is associated with increased CVD but studies on cardiovascular geographic disparities in MDS are lacking.]]></summary>
        <author>
            <name>Diego Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:35969263</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35969263/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma]]></title>
        <id>pubmed:35964234</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35964234/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: To our knowledge, this is the first report to provide evidence for clonal evolution of histiocytic sarcoma from blastoid mantle cell lymphoma based on cytogenic and molecular findings. The patient's protracted therapeutic course may have acted as an evolutionary driver promoting this transdifferentiation process.]]></summary>
        <author>
            <name>Jyoti Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology]]></title>
        <id>pubmed:35954328</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954328/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential can be defined as genetic mutations that correlate in hematologic neoplasia such as myelodysplastic syndrome. Patients with cytopenia increasingly undergo molecular genetic tests of peripheral blood or bone marrow for diagnostic purposes. Recently, a new entity has been demarcated to lessen the risk of incorrect diagnoses of hematologic malignancies. This new entity is a potential precursor of myeloid diseases, analogous to monoclonal gammopathy of...]]></summary>
        <author>
            <name>Maroun Bou Zerdan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review]]></title>
        <id>pubmed:35960050</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35960050/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.]]></summary>
        <author>
            <name>Wen-Wen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer]]></title>
        <id>pubmed:35954363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35954363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and...]]></summary>
        <author>
            <name>Lara Paracchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells]]></title>
        <id>pubmed:35953207</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35953207/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Philadelphia-negative myeloproliferative neoplasms (pH-MPNs) origin from the clonal expansion of hematopoietic stem cells with acquired mutations leading to uncontrolled proliferation of differentiated myeloid cells. The main entities of Ph-MPNs are represented by Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) that are characterized by microvascular disorders, thrombosis and bleeding, splenomegaly secondary to extramedullary hematopoiesis, various degree of bone...]]></summary>
        <author>
            <name>Laura Calabresi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy]]></title>
        <id>pubmed:35948919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Sequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.]]></summary>
        <author>
            <name>Andreas Venizelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[p73 isoforms meet evolution of metastasis]]></title>
        <id>pubmed:35948758</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948758/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer largely adheres to Darwinian selection. Evolutionary forces are prominent during metastasis, the final and incurable disease stage, where cells acquire combinations of advantageous phenotypic features and interact with a dynamically changing microenvironment, in order to overcome the metastatic bottlenecks, while therapy exerts additional selective pressures. As a strategy to increase their fitness, tumors often co-opt developmental and tissue-homeostasis programs. Herein, 25 years after...]]></summary>
        <author>
            <name>Stella Logotheti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatially resolved clonal copy number alterations in benign and malignant tissue]]></title>
        <id>pubmed:35948708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35948708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns...]]></summary>
        <author>
            <name>Andrew Erickson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection]]></title>
        <id>pubmed:35945112</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35945112/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in two antagonistic regulators of DNA methylation, DNMT3A and TET2, are associated with clonal hematopoiesis and increased risk of cardiovascular disorders. Recently, Cobo et al. traced the mechanistic bases for such links to loss of mitochondrial integrity, cytoplasmic dispersion of mitochondrial DNA, and the subsequent activation of interferon-stimulated genes (ISGs) in macrophages.]]></summary>
        <author>
            <name>Francesco Pileri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms involved in hematopoietic stem cell aging]]></title>
        <id>pubmed:35941268</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941268/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) undergo progressive functional decline over time due to both internal and external stressors, leading to aging of the hematopoietic system. A comprehensive understanding of the molecular mechanisms underlying HSC aging will be valuable in developing novel therapies for HSC rejuvenation and to prevent the onset of several age-associated diseases and hematological malignancies. This review considers the general causes of HSC aging that range from cell-intrinsic...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV]]></title>
        <id>pubmed:35940373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35940373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) with age-associated somatic mutations that disproportionally contribute to hematopoiesis generate the condition known as clonal hematopoiesis (CH). While CH conveys increased risk of hematologic cancer, there is also strong association between CH and cardiovascular disease (CVD). Accumulating evidence suggests that inflammation mechanistically links CH to CVD, and we hypothesized that CH may be a predictive biomarker of CVD in conditions of chronic inflammation....]]></summary>
        <author>
            <name>Brian Wiley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220827212147&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC]]></title>
        <id>pubmed:35941190</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35941190/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib...]]></summary>
        <author>
            <name>Kei Kunimasa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220826211902&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220819211457&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre  Tet2flox/flox G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chlo Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220825212117&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220824212808&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220823212820&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220822212717&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220821211551&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220820211309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyski</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220819211458&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220818211845&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Mire N Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220817212606&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220816212355&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220815212205&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220814211915&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220813211549&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220812210706&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220811211442&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220810210900&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220809211355&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, uksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
 NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
 VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content ]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 
 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest https://t.co/qWH2dTv8j9
 Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
 NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
 NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
 NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial ]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial  https://t.co/VbyoUJmTRJ
 NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
 Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
 NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
 Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
 NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
 NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>